Literature DB >> 21410639

Opioids: how to improve compliance and adherence.

Alessandra Graziottin1, Jacqueline Gardner-Nix, Maik Stumpf, Michael N Berliner.   

Abstract

Chronic pain has been recognized as a major worldwide health care problem. Today, medical experts and health agencies agree that chronic pain should be treated with the same priority as the disease that caused it, and patients should receive adequate pain relief. To achieve good analgesia, patient adherence to a prescribed pain treatment is of high importance. Patients with chronic pain often do not use their medication as prescribed, but change the frequency of intake. This can result in poor treatment outcomes and may necessitate additional emergency treatment, which increases the overall costs. Factors that influence adherence include knowledge of the disease, realistic treatment expectations, perceived benefit from treatment, side effects, depression, dosing frequency, and attitudes of relatives/significant others toward opioids. Addressing all these factors should ensure a good treatment outcome. Good adherence to pain therapy is associated with improved efficacy in pain relief and quality of life. Opioids have become an integral part of the treatment of moderate to severe chronic noncancer pain. They may cause unpleasant side effects such as nausea, vomiting, and constipation. Patients should be informed adequately about side effects, which should be treated pro-actively to foster adherence to treatment. Signs of tolerance, hyperalgesia, and drug abuse should be monitored as these may occur in some patients. An individualized treatment algorithm with a clear treatment goal and regular treatment reassessment is key for successful treatment. Long-acting opioids offer sustained pain relief over 24 hours with manageable side effects-they simplify treatment thereby supporting treatment adherence.
© 2011 The Authors. Pain Practice © 2011 World Institute of Pain.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21410639     DOI: 10.1111/j.1533-2500.2011.00449.x

Source DB:  PubMed          Journal:  Pain Pract        ISSN: 1530-7085            Impact factor:   3.183


  9 in total

Review 1.  Use of opioids for treatment of osteoporotic pain.

Authors:  Renato Vellucci; Rocco Domenico Mediati; Giovanna Ballerini
Journal:  Clin Cases Miner Bone Metab       Date:  2014-09

2.  Determinants of adherence to delayed-release doxylamine and pyridoxine in patients with nausea and vomiting of pregnancy.

Authors:  Maged M Costantine; Ilan Matok; Guisseppe Chiossi; Shannon Clark; Menachem Miodovnik; Jason G Umans; Steve Caritis; Gary D V Hankins; Gideon Koren
Journal:  Ther Drug Monit       Date:  2012-10       Impact factor: 3.681

3.  Daily average consumption of 2 long-acting opioids: an interrupted time series analysis.

Authors:  R Amy Puenpatom; Sheryl L Szeinbach; Larry Ma; Rami H Ben-Joseph; Kent H Summers
Journal:  Am Health Drug Benefits       Date:  2012-01

4.  Update on prescription extended-release opioids and appropriate patient selection.

Authors:  Michael J Brennan
Journal:  J Multidiscip Healthc       Date:  2013-07-23

5.  Effectiveness and Safety of Once-Daily Extended-Release Hydrocodone in Individuals Previously Receiving Immediate-Release Oxycodone for Chronic Pain.

Authors:  Joseph Pergolizzi; Maribeth Kowalski; Ellie He
Journal:  Pain Med       Date:  2018-05-01       Impact factor: 3.750

6.  Healthcare Costs And Resource Utilization In Chronic Pain Patients Treated With Extended-Release Formulations Of Tapentadol, Oxycodone, Or Morphine Stratified By Type Of Pain: A Retrospective Claims Analysis, 2012-2016.

Authors:  Vladimir Zah; Rowe B Brookfield; Martina Imro; Simona Tatovic; Jovana Pelivanovic; Djurdja Vukicevic
Journal:  J Pain Res       Date:  2019-11-08       Impact factor: 3.133

7.  Pursuing the Recovery of Severe Chronic Musculoskeletal Pain in Italy: Clinical and Organizational Perspectives from a SIAARTI Survey.

Authors:  Alessandro Vittori; Emiliano Petrucci; Marco Cascella; Massimo Innamorato; Arturo Cuomo; Antonino Giarratano; Flavia Petrini; Franco Marinangeli
Journal:  J Pain Res       Date:  2021-10-29       Impact factor: 3.133

8.  Assessment of Transdermal Buprenorphine Patches for the Treatment of Chronic Pain in a UK Observational Study.

Authors:  Mick Serpell; Shiva Tripathi; Sabine Scherzinger; Sònia Rojas-Farreras; Alexander Oksche; Margaret Wilson
Journal:  Patient       Date:  2016-02       Impact factor: 3.883

9.  Characterisation of concurrent use of prescription opioids and benzodiazepine/Z-drugs in Alberta, Canada: a population-based study.

Authors:  Vishal Sharma; Daniala Weir; Salim Samanani; Scot H Simpson; Fizza Gilani; Ed Jess; Dean T Eurich
Journal:  BMJ Open       Date:  2019-09-06       Impact factor: 2.692

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.